《大行報告》花旗上調中國中車(01766.HK)目標價至5.5元 評級「買入」
花旗發表報告,指進一步將中國中車(01766.HK)2021及2022財年的盈利預測各下調8%,以反映第三季業績疲弱,及內地鐵路投資前景低迷,但仍維持「買入」評級,因以預測市盈率和市賬率計估值均屆歷史低位,股息率(料約6%)也很有吸引力,目標價就由5.03元升至5.5元。
花旗指,管理層在分析師簡報會上表示,「十四五」的高速鐵路建設將低於「十二五」和「十三五」,而且新線路的客流密度也將低於以前。該行認為可能會影響國鐵集團採購EMU電動多功能車。
另外,該行預測,中國中車2022財年的盈利按年增長約10%,因預計2022財年起鐵路投資將在鐵路客運量恢復的推動下溫和復甦。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.